8-K - United Therapeutics Corporation | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

United Therapeutics Corporation filed an 8-K on March 9, 2026, disclosing that on March 8, 2026, its Board of Directors approved an action under Item 1.01 Entry into a Material Definitive Agreement. Item 7.01 includes Exhibit 99.1 press release dated March 9, 2026, furnished but not filed.

Key Takeaways

1Board of Directors approved action on March 8, 2026

2Item 1.01: Entry into a Material Definitive Agreement

3Item 7.01 with Exhibit 99.1 press release dated March 9, 2026

4Item 9.01 lists Exhibits 99.1 and 104 Cover Page Interactive Data File

Current Report Details

Event Type

Material Agreement

Regulation Fd

Exhibits Only

Disclosure

Mandatory

Variant

8-K

Items Reported

1.01

. Entry into a Material Definitive Agreement. On March 8, 2026, the Board of Directors (the Board ) of United Therapeutics Corporation (the Company ) approved a

Material Agreement

$2.00B$1.50B$750.0M$750.0M

7.01

and Exhibit 99.1 attached hereto are being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amend

Regulation Fd

9.01

. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description of Exhibit 99.1 Press release dated March 9, 2026 104 Cover page Interactive Data File

Exhibits Only

Source Document

Exhibits (2)

8-K

FORM 8-K

99.1

EXHIBIT 99.1